Interventional bronchoscopy for chronic obstructive pulmonary disease: more than a pipe dream

Carew, Alan M; Williamson, Jonathan P; Farah, Claude S; Saghaie, Tajalli; Phillips, Martin; Ing, Alvin

doi:10.5694/mja2.51218

ARTICLE
AUTHORS
REFERENCES

Topics

Respiratory tract diseases

Anatomy and physiology

Surgical procedures, operative

Summary

Endoscopic lung volume reduction (ELVR) is recognised in both national and international expert guidelines as one of the few additive treatments to benefit patients with advanced chronic obstructive pulmonary disease (COPD) who are otherwise receiving optimal medical and supportive care. Despite these recommendations and a growing evidence base, these procedures are not widely offered across Australia and New Zealand, and general practitioner and physician awareness of this therapy can be improved.
ELVR aims to mitigate the impact of hyperinflation and gas trapping on dyspnoea and exercise intolerance in COPD. Effective ELVR is of proven benefit in improving symptoms, quality of life, lung function and survival.
Several endoscopic techniques to achieve ELVR have been developed, with endobronchial valve placement to collapse a single lobe being the most widely studied and commonly practised.
This review describes the physiological rationale underpinning lung volume reduction, highlights the challenges of patient selection, and provides an overview of the evidence for current and investigational endoscopic interventions for COPD.

1 Macquarie Health, Sydney, NSW
2 University of Queensland, Brisbane, QLD
3 South Western Sydney Clinical School, University of New South Wales, Sydney, NSW
4 Concord Hospital, Sydney, NSW
5 Macquarie University, Sydney, NSW

Correspondence: alan.carew@uq.edu.au

Competing interests:

Alvin Ing is principal investigator in investigator‐initiated trials sponsored by Olympus Australia, Pulmonx Australia and Gala Therapeutics.

1. Australian Institute of Health and Welfare. Deaths in Australia (AIHW Cat. No. PHE 229). Canberra: AIHW, 2019. https://www.aihw.gov.au/reports/life‐expectancy‐death/deaths‐in‐australia (viewed July 2020).
2. Access Economics. Economic impact of COPD and cost effective solutions. Sydney: Access Economics, 2008. http://www.rnig.org.au/docs/EconomicImpactofCOPDandCostEffectiveSolutions‐226.pdf (viewed Jul 2020).
3. Yang IA, Brown JL, George J, et al. The COPD‐X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2020. Brisbane: Lung Foundation Australia, 2020. https://copdx.org.au/wp‐content/uploads/2020/04/COPDX‐V2‐61‐Feb‐2020‐FINAL.pdf (viewed Aug 2020).
4. Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2018; (10): CD009764.
5. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2020 report. GOLD, 2020. https://goldcopd.org/gold‐reports/ (viewed Aug 2020).
7. McDonough JE, Yuan R, Suzuki M, et al. Small‐airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365: 1567–1575.
8. Fessler HE, Scharf SM, Ingenito EP, et al. Physiologic basis for improved pulmonary function after lung volume reduction. Proc Am Thorac Soc 2008; 5: 416–420.
9. Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 187–201.
10. Barbera JA, Ramirez J, Roca J, et al. Lung structure and gas exchange in mild chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 141: 895–901.
11. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 2014; 44: 1521–1537.
12. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung‐volume‐reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–2073.
13. Clark SJ, Zoumot Z, Bamsey O, et al. Surgical approaches for lung volume reduction in emphysema. Clin Med (Lond) 2014; 14: 122–127.
14. Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic lung volume reduction: an expert panel recommendation ‐ update 2019. Respiration 2019; 97: 548–557.
15. Chew J, Mahadeva R. The role of a multidisciplinary severe chronic obstructive pulmonary disease hyperinflation service in patient selection for lung volume reduction. J Thorac Dis 2018; 10: S3335–S3343.
16. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NICE guideline [NG115]). London: NICE, 2019. https://www.nice.org.uk/guidance/ng115/chapter/Recommendations (viewed Aug 2020).
17. Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233–1244.
18. Herth FJ, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334–1342.
19. Davey C, Zoumot Z, Jordan S, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR‐HIFi study): a randomised controlled trial. Lancet 2015; 386: 1066–1073.
20. Klooster K, ten Hacken NH, Hartman JE, et al. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373: 2325–2335.
21. Valipour A, Slebos DJ, Herth F, et al. Endobronchial valve therapy in patients with homogeneous emphysema. results from the IMPACT study. Am J Respir Crit Care Med 2016; 194: 1073–1082.
22. Kemp SV, Slebos DJ, Kirk A, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med 2017; 196: 1535–1543.
23. Criner GJ, Sue R, Wright S, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med 2018; 198: 1151–1164.
24. van Geffen WH, Slebos DJ, Herth FJ, et al. Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta‐analysis. Lancet Respir Med 2019; 7: 313–324.
25. Hsu K, Williamson JP, Peters MJ, Ing AJ. Endoscopic lung volume reduction in COPD: improvements in gas transfer capacity are associated with improvements in ventilation and perfusion matching. J Bronchology Interv Pulmonol 2018; 25: 48–53.
26. Yang L, Hsu K, Williamson JP, et al. Changes in ventilation and perfusion following lower lobe endoscopic lung volume reduction (ELVR) with endobronchial valves in severe COPD. Clin Respir J 2019; 13: 453–459.
27. Hopkinson NS, Toma TP, Hansell DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005; 171: 453–460.
28. Hillerdal G, Mindus S. One‐ to four‐year follow‐up of endobronchial lung volume reduction in alpha‐1‐antitrypsin deficiency patients: a case series. Respiration 2014; 88: 320–328.
29. Darwiche K, Karpf‐Wissel R, Eisenmann S, et al. Bronchoscopic lung volume reduction with endobronchial valves in low‐FEV1 patients. Respiration 2016; 92: 414–419.
30. van Dijk M, Hartman JE, Klooster K, et al. Endobronchial valve treatment in emphysema patients with a very low DLCO. Respiration 2020; 99: 163–170.
31. Gompelmann D, Benjamin N, Bischoff E, et al. Survival after endoscopic valve therapy in patients with severe emphysema. Respiration 2019; 97: 145–152.
32. Li S, Wang G, Wang C, et al. The REACH trial: a randomized controlled trial assessing the safety and effectiveness of the Spiration® valve system in the treatment of severe emphysema. Respiration 2019; 97: 416–427.
33. Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the Spiration valve system (EMPROVE). A multicenter, open‐label randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200: 1354–1362.
34. Majid A, Labarca G, Uribe JP, et al. Efficacy of the Spiration valve system in patients with severe heterogeneous emphysema: a systematic review and meta‐analysis. Respiration 2020; 99: 62–72.
35. Gompelmann D, Heinhold T, Rötting M, et al. Long‐term follow up after endoscopic valve therapy in patients with severe emphysema. Ther Adv Respir Dis 2019; 13: 1753466619866101.
36. Herth FJ, Gompelmann D, Stanzel F, et al. Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®). Respiration 2011; 82: 36–45.
37. Come CE, Kramer MR, Dransfield MT, et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J 2015; 46: 651–662.
38. Ing A, Sullivan C, Hersch N, et al. Reversal of collateral ventilation using endobronchial polymer sealant in a patient with emphysema undergoing endoscopic lung volume reduction (ELVR) with valves: a case report and proof of concept. J Bronchology Interv Pulmonol 2020; 27: e14–e16.
39. Gompelmann D, Shah PL, Valipour A, Herth FJF. Bronchoscopic thermal vapor ablation: best practice recommendations from an expert panel on endoscopic lung volume reduction. Respiration 2018; 95: 392–400.
40. Snell G, Herth FJ, Hopkins P, et al. Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. Eur Respir J 2012; 39: 1326–1333.
41. Herth FJ, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6‐month results of the multicentre, parallel‐group, open‐label, randomised controlled STEP‐UP trial. Lancet Respir Med 2016; 4: 185–193.
42. Gompelmann D, Eberhardt R, Schuhmann M, et al. Lung volume reduction with vapor ablation in the presence of incomplete fissures: 12‐month results from the STEP‐UP randomized controlled study. Respiration 2016; 92: 397–403.
43. Shah PL, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med 2013; 1: 233–240.
44. Deslée G, Mal H, Dutau H, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema: the REVOLENS randomized clinical trial. JAMA 2016; 315: 175–184.
45. Sciurba FC, Criner GJ, Strange C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: The RENEW randomized clinical trial. JAMA 2016; 315: 2178–2189.
46. Garner JL, Kemp SV, Srikanthan K, et al. 5‐Year survival after endobronchial coil implantation: secondary analysis of the first randomised controlled trial, RESET. Respiration 2020; 99: 154–162.
47. Shah PL, Slebos DJ, Cardoso PF, et al. Bronchoscopic lung‐volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham‐controlled, multicentre trial. Lancet 2011; 378: 997–1005.
48. Snell GI, Holsworth L, Khorramnia S, et al. Feasibility and safety of a transthoracic pneumostoma airway bypass in severe emphysema patients. Respiration 2017; 93: 236–246.
49. Valipour A, Fernandez‐Bussy S, Ing AJ, et al. Bronchial rheoplasty for treatment of chronic bronchitis: 12 month results from a multi‐center study. Am J Respir Crit Care Med 2020; 202: 681–689.
50. Slebos DJ, Degano B, Valipour A, et al. Design for a multicenter, randomized, sham‐controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW‐3). BMC Pulm Med 2020; 20: 41.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Interventional bronchoscopy for chronic obstructive pulmonary disease: more than a pipe dream

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *